Pharmaceutical Market Europe – December 2024 – PMLiVE
Pharmaceutical Market Europe – December 2024 PMLiVE
Year: 2024
Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development
VANCOUVER, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (Brains Bio), a global leader in natural, GMP-compliant...
New drug shows promise against Duchenne muscular dystrophy
A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle degeneration....
Researchers reveal important themes to improve interactions between police and Black autistic youth
Please complete security verificationThis request seems a bit unusual, so we need to confirm that you're human. Please press and...
National poll suggests many parents rely on threats to manage misbehavior—from no dessert to no Santa
Please complete security verificationThis request seems a bit unusual, so we need to confirm that you're human. Please press and...
Study reveals that drinking raw milk can be a gamble
Drinking raw milk — even from a certified dairy — puts you at risk for intestinal foodborne diseases, among them...
Strauss reveals findings from probe into Salmonella incident
An investigation into Salmonella contamination at Strauss in Israel has found not all food safety procedures were consistently followed but...
FDA issues warning letters over allergen labeling failures and sanitation concerns
As part of its enforcement activities, the Food and Drug Administration sends warning letters to entities under its jurisdiction. Some...
Study finds federal needle exchange programs reduce health care costs and blood-borne infections
Please complete security verificationThis request seems a bit unusual, so we need to confirm that you're human. Please press and...
Integrative Dermatology Addresses Unmet Need
NEW YORK, NY — Integrative care, a combination of conventional and complementary therapies, should not be marginalized if the goal...
Nemolizumab Gets FDA Nod for Atopic Dermatitis
The US Food and Drug Administration (FDA) has approved nemolizumab for moderate-to-severe atopic dermatitis inadequately controlled with topical therapies in...
Will Yellowstone Continue Beyond Season 5? Well…
THAT'S ALL, FOLKS! After nearly a two-year delay, the departure of its lead actor (and the mysterious, off-screen death of...
The devolution of biosimilars regulations
Nature Biotechnology, Published online: 16 December 2024; doi:10.1038/s41587-024-02497-5After two decades of experience with biosimilars, physicochemical and in vitro biological comparison...
Publisher’s Platform: FDA should stop pushing paper around and name the lettuce supplier
— OPINION — After 31 years doing food litigation, I am seldom surprised by an announcement of a foodborne illness...
Mixed Signals From Trials of Perioperative, Neoadjuvant Immunotherapy for Early TNBC
Meeting Coverage > SABCS — Adding atezolizumab, camrelizumab to chemotherapy improves pCR but not survival endpoints by Charles Bankhead, Senior...
A Setback for TNBC Monitoring With Circulating Tumor DNA in ZEST Trial
Meeting Coverage > SABCS — Study was stopped early due to enrollment issues, but lessons can still be learned by...
‘We’re Putting Teflon in Our Mouth’: What We Heard This Week
Perspectives > What We Heard This Week — Quotable quotes heard by MedPage Today's reporters by MedPage Today Staff December...
MORGONN MCMICHAEL: FDA considers banning Red Dye No. 3 in food products
The dye is already prohibited in European Union countries and will be banned in food products sold or produced in...
Been drinking and your heart’s fluttering? You may have ‘holiday heart’
Please complete security verificationThis request seems a bit unusual, so we need to confirm that you're human. Please press and...
A Psychiatrist’s Prescription for Americans’ Anger
Perspectives > Second Opinions — Courage, imagination, and the will to rebuild are key ingredients by Arthur Lazarus, MD, MBA...
